REVB REVELATION BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1810560 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.6%
TTM EPS YoY122.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-133.4%
ROA-106.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.98x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-18.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $4.06M | $3.55M | $4.15M | $5.38M | $6.91M |
| SG&A expense | $5.01M | $4.43M | $4.51M | $5.49M | $5.04M |
| Operating income | -$9.07M | -$7.98M | -$8.66M | -$10.86M | -$11.95M |
| Interest expense | — | — | — | — | $41,759 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.91M | -$15.04M | -$120,254 | -$10.83M | -$11.99M |
| EBITDA | -$9.04M | -$7.95M | -$8.63M | -$10.84M | -$11.93M |
| EPS (basic) | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 |
| EPS (diluted) | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 |
| Weighted avg. shares (diluted) | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 |
| Balance sheet | |||||
| Cash & equivalents | $10.70M | $6.50M | $11.99M | $5.25M | $1.27M |
| Current assets | $10.81M | $6.57M | $12.15M | $5.41M | $1.91M |
| PP&E, net | $18,067 | $56,332 | $65,084 | $90,133 | $115,181 |
| Total assets | $11.58M | $6.62M | $12.21M | $5.50M | $2.04M |
| Current liabilities | $2.00M | $1.91M | $5.56M | $4.45M | $2.14M |
| Total liabilities | $2.72M | $1.91M | $5.56M | $4.45M | $2.14M |
| Shareholders' equity | $8.86M | $4.71M | $6.65M | $1.05M | -$99,470 |
| Shares outstanding | 226,330 | 43,526 | 16,484 | 77,375 | 282,039 |
| Cash flow statement | |||||
| Operating cash flow | -$8.27M | -$18.32M | -$7.29M | -$11.22M | -$11.09M |
| Capital expenditure | — | $19,171 | — | — | $131,963 |
| Free cash flow | — | -$18.34M | — | — | -$11.22M |
| Investing cash flow | — | -$19,171 | — | — | -$131,963 |
| Financing cash flow | $12.47M | $12.85M | $14.03M | $15.20M | $8.00M |
| Depreciation & amortization | $27,058 | $27,923 | $25,049 | $25,048 | $16,782 |
| Stock-based compensation | $595,368 | $168,850 | $155,721 | $301,116 | $470,878 |
| Share buybacks | — | — | — | — | $35.50M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.